Needham & Company LLC restated their hold rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. Other analysts also ...
Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...
The stock's fall snapped a three-day winning streak.
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...
Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...
Robinhood reported fourth-quarter revenue of $1.01 billion, up 115% year-over-year and a new company record. The revenue ...
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
Most U.S. stocks fell Wednesday after a report showed inflation is unexpectedly worsening for Americans. The S&P 500 dropped 0.3%, though it had been on track for a much worse loss of 1.1% at the ...
Evercore ISI analyst Umer Raffat maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback